sector coverage
Health Care research
Health Care coverage collects dated research on business quality, return drivers, balance-sheet resilience, and what the market is paying for.
15 editions linked in this hub.
Coverage
- 27 Aug 2026Ramsay's theatres ran fuller while return on capital stopped at 4.6%Ramsay Health Care (ASX:RHC) rallied 13.7% as Australian hospital margins recovered. The numbers show how much of the turnaround A$50.06 now assumes.
- 25 Aug 2026Nanosonics fell 17%. CORIS now has 30 sites to justify the spendNanosonics Limited (ASX:NAN) fell 17.1% after FY26 results as CORIS costs outran sales. The next 30 sites now carry the valuation case.
- 25 Aug 2026TME Pharma added €6.3 million before choosing the bank that will seek a partnerTME Pharma (EURONEXT-PARIS:ALTME) jumped 74.9% on six adviser bids. The filings show what a bank mandate must deliver before cash runs down.
- 23 Aug 2026A US$40 million payment separates Telix's profit from an operating lossTelix Pharmaceuticals (ASX:TLX) fell 10.1% after H1 results. Its Regeneron payment and pipeline costs make the reaction look proportionate.
- 22 Aug 2026Werewolf doubled on a merger that leaves legacy holders with 6.8%Werewolf Therapeutics (NASDAQ:HOWL) rose 102.6% on the Ambros merger. The ownership split explains why the jump is less exuberant than it looks.
- 12 Aug 2026Lakefront's first results after Ouro put €734 million behind two published autoimmune patientsLakefront Biotherapeutics (EURONEXT-AMSTERDAM:LKFT) rose 3.84% after H1 results. We trace what €734 million bought and what its cash still covers.
- 11 Aug 2026A 15-patient trial wiped out Sionna's platform premium. Cash now exceeds market valueSionna Therapeutics (NASDAQ:SION) fell 91.2% after SION-719 missed its key activity endpoint. We test what cash protects after the platform reset.
- 11 Aug 2026Sobi's $75m cheque changes Innate Pharma's runway before Phase IIIInnate Pharma (EURONEXT-PARIS:IPH) gained 21.49% after licensing lacutamab. The cash matters; the $580m headline still depends on Phase III.
- 11 Aug 2026Oxford Biomedica's £40m guidance hole exposes the limits of backlog visibilityOxford Biomedica (LSE:OXB) cut FY26 revenue guidance by £40m at the midpoint. The filings show why backlog is not the same as cash.
- 5 Aug 2026Neuren's DAYBUE pop prices a royalty upgrade before Japan answersNeuren Pharmaceuticals (ASX:NEU) jumped after DAYBUE sales upgraded royalties; we test whether the rally outruns pipeline proof.
- 29 July 2026CSL's Horizon 2 rally prices yield optionality before trials beginCSL (ASX:CSL) jumped after its Horizon 2 plasma update. We test whether yield upside can offset the later trial clock.
- 13 July 2026ResMed's sleep-apnoea selloff tests whether GLP-1 fear can outweigh device evidenceResMed (ASX:RMD) fell 4.7% as sleep-apnoea sentiment weakened. We test whether device demand still supports the valuation.
- 10 July 2026Mesoblast's Ryoncil pop prices a launch before cash discipline is provenMesoblast (ASX:MSB) jumped on Ryoncil revenue. The question is whether the first US$115m year changes the cash-burn valuation math.
- 29 June 2026Neuren's European Daybue jump puts one-drug royalties ahead of the pipelineNeuren (ASX:NEU) jumped after Daybue won an EU approval positive opinion; the question is how much royalty duration the tape just capitalised.
- 24 June 2026Pro Medicus's contract wins are real; its 160-times multiple is the wagerPro Medicus (ASX:PME) keeps winning marquee US imaging contracts, but a ~160x multiple is the real wager. We test whether 20%+ growth can outrun the valuation.